Clinical Trials Logo

Cisplatin Adverse Reaction clinical trials

View clinical trials related to Cisplatin Adverse Reaction.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05247671 Not yet recruiting - Clinical trials for Cisplatin Adverse Reaction

Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity

Start date: February 15, 2022
Phase:
Study type: Observational

Approximately one-third of all patients treated with cisplatin develop renal dysfunction after a single dosage of cisplatin. Germline genetic polymorphisms may cause variations in cisplatin pharmacokinetics and in the ability of epithelial kidney cells to take up cisplatin and repair cisplatin-induced Deoxyribonucleic Acid (DNA) damage. Knowledge concerning which genotypes are associated with cisplatin-induced nephrotoxicity may help to identify at-risk patients and initiate strategies, such as using lower or fractionated cisplatin doses or avoiding cisplatin altogether, to prevent Acute Kidney Injury (AKI).